To minimize loss of clonal plasma cell populations over time and enable clinical implementation, we developed a rapid screening platform to measure ex vivo sensitivity of the MMDP in CD138+ MM primary cells with 24 h drug exposure. Here, SDC1 is linked to Miyoshi myopathy.